Portfolio Company · Operating Co.

Avere Therapeutics

Life Sciences

backed byGeneral Atlantic

CurrentLife Sciences

Avere Therapeutics

a portfolio company of

General Atlantic

Status on record: Current

Investment year: 2026

PE Firm Index

Who owns Avere Therapeutics?

Avere Therapeutics is listed as a current portfolio company of General Atlantic on General Atlantic's own portfolio page. General Atlantic has owned Avere Therapeutics since 2026, per General Atlantic's portfolio page.

Company Snapshot

Avere Therapeutics is a Life Sciences company. Its owner on record, General Atlantic, is a growth equity firm founded in 1980, headquartered in New York City, United States, with $125.3 billion under management. General Atlantic lists at least 40 companies in the index, 6 of them in Life Sciences.

SectorLife Sciences

Parent PE firmGeneral Atlantic

Ownership statusCurrent

WebsiteNot on record

About the owner

General Atlantic

Headquarters: New York City, United States
Founded: 1980
AUM: $125.3 billion
Strategy: Growth Equity
Target size: $490 million to $870 million (based on reported deals)
Sectors: Technology, Consumer, Financial Services
Companies in the index: At least 40

General Atlantic is a leading global growth equity firm that provides capital and strategic support to growth-stage companies across various sectors.

Read the General Atlantic profile

Questions about Avere Therapeutics

Who owns Avere Therapeutics?

What sector is Avere Therapeutics in?

Avere Therapeutics is in Life Sciences. Classified from the owner's portfolio label.

Where is General Atlantic headquartered?

General Atlantic is headquartered in New York City, United States.

What else does General Atlantic own in Life Sciences?

General Atlantic lists 5 other Life Sciences companies in the index, including Expedition Therapeutics, Legent, Nurix Therapeutics, Seaport Therapeutics and U.S. Urology Partners.

Sources

General Atlantic
https://www.generalatlantic.com/investments/

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with Avere Therapeutics and does not provide investment advice.

Other portfolio companies of General Atlantic

6 of 39 shown

See the full General Atlantic portfolio.

Other Life Sciences companies held by General Atlantic

Expedition Therapeutics Legent

Nurix Therapeutics Seaport Therapeutics TEAM Services Group U.S. Urology Partners

Other Life Sciences portfolio companies

via Wavemaker 360 Health

3P Biopharmaceuticals

via Marlin Equity Partners

Browse PE-backed companies.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

General Atlantic

New York City, United States

Status: Current

Investment year: 2026

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.